u/honest_syringe_2025

Strongly agree. The regain is expected.

The telehealth + compounding combo cost telehealth plus 23% markup. Not cheap but covered by insurance depending on state.

This is correct. Discontinuation data is real.

appetite return timelines vary interval stretching

This is correct. 2mL versus 21mL is the common mistake.

Small correction: the trial was 13 weeks, not 35.

Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.

Small correction: the trial was 13 weeks, not 35. Does not change your point but people will quote it.

Respectfully this is a sample of one presented as a finding.

regulatory claims need a citation to the actual rule, not interpretation

telehealth prescriber models exist, pricing differs by state

This is the correct method framing. Column and gradient are load-bearing fields.

Dead space in the needle hub holds a small but non-trivial volume. On low-volume draws that can be several units.

This is correct. 3mL versus 15mL is the common mistake.

Small correction: the trial was 11 weeks, not 3. Does not change your point but people will quote it.

Strongly agree. Heart rate escalation needs the actual data, not impressions.

This is correct. 2mL versus 3mL is the common mistake.

area% and mass% are not the same and this whole post conflates them

This is the correct method framing. Column and gradient are load-bearing fields.

phase 2 numbers are not maintenance numbers, cite the trial

Adding to this: triple agonist is doing more work than the comment implies.